Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID‐19 infection. Issue 3 (13th November 2021)

• Record Type: Journal Article
• Authors: Bronstein, Yotam; Adler, Amos; Katash, Haytham; Halutz, Ora; Herishanu, Yair; Levytskyi, Katia
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 94:Issue 3(2022)
• Page Start: 1241
• Page End: 1245
• Publication Date: 2021-11-13
• Subjects: bamlanivimab -- convalescent plasma -- COVID‐19 -- immunocompromised -- SARS‐CoV‐2 -- Spike gene; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27445
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Immunocompromised patients have an increased risk of persistent COVID‐19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti‐SARS‐CoV‐2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody‐resistant SARS‐CoV‐2 infections evolution in immunocompromised patients. Highlights: Patients with hematologic malignancies are at risk of persistent SARS‐CoV‐2 infection. Using anti‐SRAS‐CoV‐2 antibody preparations in immunocompromised patients may lead to the evolution of antibody‐resistant SRAS‐CoV‐2 infections. Antibody‐resistant SRAS‐CoV‐2 infections might have severe epidemiological implications.